The price of health: unveiling the cost of diabetes treatment in Kingdom of Saudi Arabia (KSA); A systematic literature review protocol

Pharmacy Practice

  • Mohammed Kanan1Department of Clinical Pharmacy, King Fahad Medical City, Riyadh, 12211, Kingdom of Saudi Arabia., 2Department of Pharmaceutical Care, Rafha General Hospital, Rafha, 76411, Kingdom of Saudi Arabia.
  • Bader Alharbi3Pharmacy Services Department, Johns Hopkins Aramco Healthcare (JHAH), Dhahran, Saudi Arabia.
  • Ahmed Alshammari4Department of Medical Supply, Rafha General Hospital, Rafha, 76411, Saudi Arabia.
  • Rahaf Alshammari5Pharmacy Department, King Fahad Specialty Hospital, Tabuk, Saudi Arabia.
  • Abrar Alsayed6Pharmacy Department, Royal Commission Hospital, Yanbu, Saudi Arabia.
  • Budur Alshammari7Department of Pharmacy Services, Maternity and Children Hospital, Rafha, Northern Borders Health Cluster, Saudi Arabia.
  • Norah Aldhfiri8Department of Pharmacy Services, Northern Area Armed Forces Hospital, King Khalid Military, Hafr Al Batin, 31991, Saudi Arabia.
  • Mohammed Bamuflih9Department of Medicine, King Abdulaziz University, 22230, Jeddah, Saudi Arabia.
  • Moussa Alkhateeb9Department of Medicine, King Abdulaziz University, 22230, Jeddah, Saudi Arabia.
  • Reem Alqahtani10Department of Medicine, King Khalid University, Abha, 62217, Saudi Arabia.
  • Nawal Asiri10Department of Medicine, King Khalid University, Abha, 62217, Saudi Arabia.
  • Waad Alnami10Department of Medicine, King Khalid University, Abha, 62217, Saudi Arabia.
  • Reema Alghaseb10Department of Medicine, King Khalid University, Abha, 62217, Saudi Arabia.
  • Abdullah Almatrafi11Department of Medicine, Qassim University, Qassim, 81411, Saudi Arabia.
  • Raghad Jan12Department of Medicine, Taibah University, Madina, 42220, Saudi Arabia.

Volume 22 Issue 3 Pages 1-7

DOI: 10.18549/PharmPract.2024.3.2972

Abstract

Background: Non-communicable diseases (NCDs) place significant financial burdens on individuals, communities, and countries. However, very little information is available regarding the extent of diabetes expenses in the Kingdom of Saudi Arabia (KSA). As far as we are aware, no comprehensive systematic literature review on diabetes cost in KSA has been published yet. Objective: The purpose of the analysis is to gather information about the direct and indirect costs of diabetes mellitus in KSA from the literature, examine the techniques employed to estimate costs, and discover potential avenues for further investigation. Methods: A systematic literature search will be performed to identify studies that reported the cost of diabetes mellitus in KSA. A rigorous literature search will be conducted using the following academic electronic databases: Scopus, Medline (via PubMed), Cochrane, Springer, Science Direct, and Web of Science. The eligibility criteria employed for the study will encompass the following aspects: examination of peer-reviewed articles in English which were published within the timeframe of 2010 to 2023, articles presenting novel research outcomes regarding the cost of diabetes mellitus, and studies conducted in KSA. To gather the necessary information, data will be extracted in sheets, and the results will be systematically arranged within tables. Results: We have reviewed the cost of diabetes mellitus. Extracted articles will be analyzed in the results based on the direct and indirect costs per patient of diabetes mellitus. The papers will be analyzed on the bases of study design, data source, perspective, and the healthcare cost categories. Conclusion: Different approaches will be employed to calculate healthcare costs associated with diabetes mellitus.

Keywords

  • cost
  • direct cost
  • Indirect cost
  • cost of illness
  • antidiabetic medication
  • kingdom of Saudi Arabia
Pharmacy Practice

Loading…